Protocol for a pilot randomised controlled trial of zoledronic acid to prevent bone loss following sleeve gastrectomy surgery
Authors:
Open Access
Abstract
Introduction Sleeve gastrectomy (SG) is an increasingly used and effective treatment for obesity; however, the rapid weight loss associated with SG adversely affects bone metabolism predisposing patients to skeletal fragility. Bisphosphonate medications have been evaluated for safety and efficacy in combating bone loss in patients with osteoporosis, but their use in SG-induced bone loss is limited. The goal of this study is to investigate how a one-time infusion of zoledronic acid compares to placebo, in its ability to combat SG-associated bone loss. Methods and analysis This research protocol is a 9-month, pilot randomized controlled trial (RCT) involving 30 adult SG patients randomised to receive an infusion of either 5 mg of zoledronic acid or placebo, 6 weeks following surgery. To be included participants must be Ethics and dissemination This study was approved by the Institutional Review Board of the University of Nebraska Medical Center (IRB820-19). Written consent will be obtained from participants at enrolment by trained staff. Careful and thorough explanation are used in obtainment of consent and voluntariness is emphasised throughout the trial. The findings of this study will be presented locally, nationally, and published in peer-reviewed journals. Additional details will be reported on ClinicalTrials.gov. Trial registration number NCT04279392Keywords
Funding Information
- University of Nebraska Medical Center (NA)
- Society of American Gastrointestinal and Endoscopic Surgeons (NA)
This publication has 37 references indexed in Scilit:
- Bisphosphonates adherence for treatment of osteoporosisInternational Archives of Medicine, 2013
- Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with DiabetesNew England Journal of Medicine, 2012
- Bisphosphonates: Mechanism of Action and Role in Clinical PracticeMayo Clinic Proceedings, 2008
- Bone Mineral Density Changes during the Menopause Transition in a Multiethnic Cohort of WomenThe Journal of Clinical Endocrinology & Metabolism, 2008
- Prolonged Efficacy of a Single Dose of the Bisphosphonate Zoledronic AcidClinical Cancer Research, 2007
- Bone turnover 18 months after a single intravenous dose of zoledronic acidInternational Journal Of Clinical Practice, 2007
- Once-Yearly Zoledronic Acid for Treatment of Postmenopausal OsteoporosisNew England Journal of Medicine, 2007
- A systematic review of the Human Activity ProfileClinical Rehabilitation, 2007
- Long-Term Control of Bone Turnover in Paget's Disease With Zoledronic Acid and RisedronateJournal of Bone and Mineral Research, 2007
- Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO reportOsteoporosis International, 1994